A combination of neuropsychological, neuroimaging, and cerebrospinal fluid markers predicts conversion from mild cognitive impairment to dementia

Journal of Alzheimer's Disease

Volumn 36, Issue 3, 2013, Pages 421-431

  Eckerström, Carl ^a   Olsson, Erik ^a   Bjerke, Maria ^a   Malmgren, Helge ^a   Edman, Åke ^a   Wallin, Anders ^a   Nordlund, Arto ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Alzheimer's disease; cerebrospinal fluid; dementia; mild cognitive impairment; neuroimaging; neuropsychology

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; P TAU PROTEIN; T TAU PROTEIN; TAU PROTEIN; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MALE; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PREDICTION; PRIORITY JOURNAL; VOLUMETRY;

EID: 84880880891     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-122440     Document Type: Article

References (50)

1. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, Nordberg A, Backman L, Albert M, Almkvist O, Arai H, Basun H, Blennow K, de Leon M, DeCarli C, Erkinjuntti T, Giacobini E, Graff C, Hardy J, Jack C, Jorm A, Ritchie K, van Duijn C, Visser P, Petersen RC (2004) Mild cognitive impairment-beyond controversies, towards a consensus: Report of the International Working Group on Mild Cognitive Impairment. J Intern Med 256, 240-246
2. Mitchell AJ, Shiri-Feshki M (2009) Rate of progression of mild cognitive impairment to dementia-meta-Analysis of 41 robust inception cohort studies. Acta Psychiatr Scand 119, 252-265
3. Petersen RC (2009) Early diagnosis of Alzheimer's disease: Is MCI too late? Curr Alzheimer Res 6, 324-330
4. Forlenza OV, Diniz BS, Nunes PV, Memoria CM, Yassuda MS, Gattaz WF (2009) Diagnostic transitions in mild cognitive impairment subtypes. Int Psychogeriatr 21, 1088-1095
5. Nordlund A, Rolstad S, Klang O, Edman A, Hansen S,Wallin A (2010) Two-year outcome of MCI subtypes and aetiologies in the GoteborgMCI study. J Neuro Neurosurg Psychiatry 81, 541-546
6. Espinosa A, Alegret M, Valero S, Vinyes-Junque G, Hernandez I, Mauleon A, Rosende-Roca M, Ruiz A, Lopez O, Tarraga L, Boada M (2013) A longitudinal follow-up of 550 mild cognitive impairment patients: Evidence for large conversion to dementia rates and detection of major risk factors involved. J Alzheimers Dis 34, 769-780
7. Tales A, Haworth J, Wilcock G, Newton P, Butler S (2008) Visual mismatch negativity highlights abnormal preattentive visual processing in mild cognitive impairment and Alzheimer's disease. Neuropsychologia 46, 1224-1232
8. Jicha GA, Abner E, Schmitt FA, Cooper GE, Stiles N, Hamon R, Carr S, Smith CD, MarkesberyWR(2008) Clinical features of mild cognitive impairment differ in the research and tertiary clinic settings. Dement Geriatr Cogn Disord 26, 187-192
9. Alegret M, Cuberas-Borros G, Vinyes-Junque G, Espinosa A, Valero S, Hernandez I, Roca I, Ruiz A, Rosende-Roca M, Mauleon A, Becker JT, Castell-Conesa J, Tarraga L, BoadaM (2012) A two-year follow-up of cognitive deficits and brain perfusion in mild cognitive impairment and mild Alzheimer's disease. J Alzheimers Dis 30, 109-120
10. Nordlund A, Rolstad S, Gothlin M, Edman A, Hansen S, Wallin A (2010) Cognitive profiles of incipient dementia in the Goteborg MCI study. Dement Geriatr Cogn Disord 30, 403-410
11. Chapman RM, Mapstone M, McCrary JW, Gardner MN, Porsteinsson A, Sandoval TC, Guillily MD,Degrush E, Reilly LA (2011) Predicting conversion from mild cognitive impairment to Alzheimer's disease using neuropsychological tests and multivariate methods. J Clin Exp Neuropsychol 33, 187-199
12. Frisoni GB, Fox NC, Jack CR, Jr., Scheltens P, Thompson PM (2010) The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol 6, 67-77
13. van de Pol L, Gertz HJ, Scheltens P,WolfH(2011) Hippocampal atrophy in subcortical vascular dementia. Neurodegener Dis 8, 465-469
14. Hansson O, ZetterbergH, Buchhave P, Londos E, BlennowK, Minthon L (2006) Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: A follow-up study. Lancet Neurol 5, 228-234
15. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosen E, Aarsland D, Visser PJ, Schroder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttila T, Wallin A, Jonhagen ME, Minthon L, Winblad B, Blennow K (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA302, 385-393
16. Eckerstrom C, Andreasson U, Olsson E, Rolstad S, Blennow K, Zetterberg H, Malmgren H, Edman A, Wallin A (2010) Combination of hippocampal volume and cerebrospinal fluid biomarkers improves predictive value in mild cognitive impairment. Dement Geriatr Cogn Disord 29, 294-300
17. Morinaga A, Ono K, Ikeda T, Ikeda Y, Shima K, Noguchi-Shinohara M, Samuraki M, Yanase D, Yoshita M, Iwasa K, Mastunari I, Yamada M (2010) A comparison of the diagnostic sensitivity of MRI, CBF-SPECT, FDG-PET and cerebrospinal fluid biomarkers for detecting Alzheimer's disease in a memory clinic. Dement Geriatr Cogn Disord 30, 285-292
18. Vemuri P,Wiste HJ,Weigand SD, ShawLM, Trojanowski JQ, WeinerMW, Knopman DS, Petersen RC, Jack CR, Jr. (2009) MRI and CSF biomarkers in normal, MCI, and AD subjects: Predicting future clinical change. Neurology 73, 294-301
19. Shaffer JL, Petrella JR, Sheldon FC, Choudhury KR, Calhoun VD, Coleman RE, Doraiswamy PM (2013) Predicting cognitive decline in subjects at risk for Alzheimer Disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers. Radiology 266, 583-591
20. Devanand DP, Liu X, Tabert MH, Pradhaban G, Cuasay K, Bell K, de Leon MJ, Doty RL, Stern Y, Pelton GH (2008) Combining early markers strongly predicts conversion from mild cognitive impairment to Alzheimer's disease. Biol Psychiatry 64, 871-879
21. Fleisher AS, Sun S, Taylor C, Ward CP, Gamst AC, Petersen RC, Jack CR, Jr., Aisen PS, Thal LJ (2008) Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment. Neurology 70, 191-199
22. Liu Y, Paajanen T, Zhang Y, Westman E, Wahlund LO, Simmons A, Tunnard C, Sobow T, Mecocci P, Tsolaki M, Vellas B, Muehlboeck S, Evans A, Spenger C, Lovestone S, Soininen H (2010) Analysis of regional MRI volumes and thicknesses as predictors of conversion from mild cognitive impairment to Alzheimer's disease. Neurobiol Aging 31, 1375-1385
23. Herukka SK, Helisalmi S, Hallikainen M, Tervo S, Soininen H, Pirttila T (2007) CSF Abeta42, Tau and phosphorylated Tau, APOE epsilon4 allele and MCI type in progressive MCI. Neurobiol Aging 28, 507-514
24. Ewers M, Walsh C, Trojanowski JQ, Shaw LM, Petersen RC, Jack CR, Jr., Feldman HH, Bokde AL, Alexander GE, Scheltens P, Vellas B, Dubois B,Weiner M, Hampel H (2012) Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. Neurobiol Aging 33, 1203-1214
25. Landau SM, Harvey D, Madison CM, Reiman EM, Foster NL, Aisen PS, Petersen RC, Shaw LM, Trojanowski JQ, Jack CR, Jr., Weiner MW, Jagust WJ (2010) Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 75, 230-238
26. Cui Y, Liu B, Luo S, Zhen X, Fan M, Liu T, Zhu W, Park M, Jiang T, Jin JS (2011) Identification of conversion from mild cognitive impairment to Alzheimer's disease using multivariate predictors. PloS one 6, e21896
27. Schmand B, Huizenga HM, van Gool WA (2010) Metaanalysis of CSF and MRI biomarkers for detecting preclinical Alzheimer's disease. Psychol Med 40, 135-145
28. Nordlund A, Rolstad S, Hellstrom P, Sjogren M, Hansen S, Wallin A (2005) The Goteborg MCI study: Mild cognitive impairment is a heterogeneous condition. J Neurol Neurosurg Psychiatry 76, 1485-1490
29. Wallin A, Edman A, Blennow K, Gottfries CG, Karlsson I, Regland B, Sjogren M (1996) Stepwise comparative status analysis (STEP): A tool for identification of regional brain syndromes in dementia. J Geriatr Psychiatry Neurol 9, 185-199
30. Royall DR, Mahurin RK, GrayKF(1992) Bedside assessment of executive cognitive impairment: The executive interview. J Am Geriatr Soc 40, 1221-1226
31. Folstein MF, Folstein SE, McHugh PR (1975) "Minimental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198
32. Morris JC (1997) Clinical dementia rating: A reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int Psychogeriatr 9(Suppl 1), 173-176; discussion 177-178
33. American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders (DSM-IV). American Psychiatric Association, Washington, D.C.
34. Reisberg B, Ferris SH, de Leon MJ, Crook T (1988) Global Deterioration Scale (GDS). Psychopharmacol Bull 24, 661-663
35. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944
36. Erkinjuntti T, Inzitari D, Pantoni L, Wallin A, Scheltens P, Rockwood K, Roman GC, Chui H, Desmond DW (2000) Research criteria for subcortical vascular dementia in clinical trials. J Neural Transm Suppl 59, 23-30
37. The Lund and Manchester Groups (1994) Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups. J Neurol Neurosurg Psychiatry 57, 416-418
38. Wrangsjö A (2004) A Bayesian framework for image denoising (Thesis). Institute of Technology, Linköping University, Linköping
39. Eckerstrom C, Olsson E, Borga M, Ekholm S, Ribbelin S, Rolstad S, Starck G, Edman A,Wallin A, Malmgren H (2008) Small baseline volume of left hippocampus is associated with subsequent conversion of MCI into dementia: The Goteborg MCI study. J Neurol Sci 272, 48-59
40. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E (1995) Tau protein in cerebrospinal fluid: A biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 26, 231-245
41. Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van Der Perre B, Sjogren M, Andreasen N, Blennow K (2000) Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: A sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 285, 49-52
42. Vanderstichele H, Blennow K, D'Heuvaert N, Buyse MA, Wallin A, Andreasen N, Seubert P, Van de Voorde A, Vanmechelen E (1998) Development of a specific diagnostic test for measurement of beta-Amyloid (1-42) [beta A(4)(1-42)] in CSF. Prog Alzheimers Parkinsons Dis 49, 773-778
43. Eriksson L, Johansson E, Kettaneh-Wold N, Wikström C, Wold S (2002) User's guide to Simca-P. Umetrics AB, Ume°a, Sweden
44. Johnson DK, Storandt M, Morris JC, Galvin JE (2009) Longitudinal study of the transition from healthy aging to Alzheimer disease. Arch Neurol 66, 1254-1259
45. Weintraub S,WicklundAH,SalmonDP(2012) The neuropsychological profile of Alzheimer disease. Cold Spring Harb Perspect Med 2, a006171
46. Binetti G, Cappa SF, Magni E, Padovani A, Bianchetti A, TrabucchiM(1996) Disorders of visual and spatial perception in the early stage of Alzheimer's disease. Ann N Y Acad Sci 777, 221-225
47. Schmand B, Eikelenboom P, van Gool WA (2012) Value of diagnostic tests to predict conversion to Alzheimer's disease in young and old patients with amnestic mild cognitive impairment. J Alzheimers Dis 29, 641-648
48. Blennow K, Vanmechelen E, Hampel H (2001) CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease. Mol Neurobiol 24, 87-97
49. Caselli RJ, Reiman EM (2013) Characterizing the preclinical stages of Alzheimer's disease and the prospect of presymptomatic intervention. J Alzheimers Dis 33(Suppl 1), S405-S416
50. Jack CR, Jr., Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9, 119-128